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Abstract 
 
We investigated the relationships between functional genetic variants of 5-HT2C 
receptor and multi drug resistant protein (MDR1), coding for P-glycoprotein, and 
second generation antipsychotic (SDA)-induced weight gain among 108 female 
schizophrenic patients treated with olanzapine or risperidone for up to 4 months. No 
significant differences in -759C/T allelic and genotype variants of 5HT2C  were found 
between patients who gained more than 7% of their initial weight compared to those 
who gained less. Haplotype based analysis of two MDR1 loci - exon 21 G2677T and 
exon 26 C3435T revealed borderline less representation of the G2677/C3435 
haplotype in ≥7% group. In the subgroup of patients treated with risperidone, we 
found borderline overrepresentations of 2677T and significant overrepresentations of 
3435T variant and borderline overrepresentation of 2677T/3435T haplotype the ≥7% 
group, whereas G2677/C3435 haplotype was found to be less represented in the ≥7% 
group. Our data indicate a non significant role of 759C/T 5HT2C in SDAs-induced 
weight gain, and stronger influence of MDR1 G2677T and C3435T polymorphisms 
on risperidone-induced weight gain in female schizophrenic patients. 3435T and 
2677T MDR1 variants, both associated with lower P-gp function might predispose to 
higher risperidone accessibility to the brain allowing its stronger effects, including 
weight gain. 
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1. Introduction 
 
1.1. Weight gain and serotonin receptor 5-HT2C 
 
Weight gain is one of the major side effects of treatment with second generation 
antipsychotics (SDAs) (Sussman, 2001) increasing morbidity and often leading to the 
lack of compliance with the patient thus influencing the outcome of the treatment 
itself (Lee and Paffenbarger, 1992). Gene polymorphisms of target receptors that 
could serve as potential gene markers in the prediction of side-effects, including 
weight gain, have been extensively studied. Serotonin receptor 5-HT2C, on which, both 
olanzapine and risperidone have strong antagonistic effects (Stahl, 2000; Di Matteo et 
al., 2002), is one of the major gene candidates for SDAs-induced weight gain (Tecott 
et al.,1995). According to several studies the role of -759C/T promoter polymorphism 
in SDAs-induced weight gain is particularly interesting, however, the results are far 
from being consistent (Basile et al., 2002; Reynolds et al., 2002; Tsai et al., 2002; 
Theisen et al., 2004; Ellingrod et al., 2005; Miller et al., 2005; Godlewska et al., 
2006).  
 
1.2. Weight gain and P-glycoprotein 
 
SDAs-induced weight gain is thought to be dose independent (Kinon et al., 2001). 
However, apart from dose, plasma olanzapine and risperidone levels and their access 
to the brain might depend upon multidrug resistant protein gene (MDR1 or ABCB1), 
which codes for P-glycoprotein (P-gp), the transmembrane efflux transporter. P-gp 
plays a major role in absorption, distribution and elimination of drugs (Lin and 
Yamazaki, 2003). Furthermore, it is widely localized in the luminal membranes of 
endothelial cells in cerebral capillaries forming the blood-brain barrier (Cordon-Cardo 
et al., 1989). Studies using mice models showed P-glycoprotein-deficient mice to 
have 10 times higher drug concentrations (Uhr et al., 2006). P-gp may in various 
degrees influence the access of antipsychotics to the brain, and olanzapine was ranked 
as an intermediate (Boulton et al., 2002) and risperidone as a strong P-gp substrate 
(Mahar Doan et al., 2002). 
Two functional single nucleotide polymorphisms (SNP), silent mutation C3435T in 
exon 26 and exon 21 SNP G2677T were extensively studied through their influence 
on expression of MDR1 (Hoffmeyer et al., 2000; Tanabe et al., 2001), their 
association with pharmacokinetics, bioavailability and clinical effects of drugs (Uhr et 
al., 2006; Roberts et al., 2002). As to our knowledge, only one recent association 
study of weight gain and MDR1 polymorphisms was performed reporting negative 
findings (Lin et al., 2006). Considering the role of P-gp in forming blood-brain barrier 
which influences olanzapine and risperidone access, we hypothesized that functional 
polymorphisms of MDR1 gene might influence weight gain. 
 Therefore, the aim of the study was to investigate the potential influence of 5-
HT2C (promoter region -759C/T) and MDR1 polymorphisms (exon 26 C3435T and 
exon 21 G2677T) on olanzapine and risperidone-induced weight gain in female 
schizophrenic patients. 
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2. Methods 
 
2.1. Subjects 
 
This study included 108 adult schizophrenic female patients, of Croatian descent, 
referred to the Department of Psychiatry, University Hospital Centre Zagreb and 
psychiatric hospital “Sveti Ivan”. 52 out of 108 female patients were included in a 
previous study by our group, described in Bozina et al., (2006). Inclusive criteria, 
diagnosis and illness description were the same as described in the mentioned 
publication. All patients were experiencing their acute phase of the illness. 96 patients 
had received no antipsychotic medication prior to olanzapine or risperidone 
admission, and 12 patients had received typical antipsychotics (haloperidol or 
fluphenazine) during the course of their illness, but have stopped taking their 
medication prior to this study (mean+/-SD was 35+/-10 days). The mean +/- SD age, 
years of education, and duration of illness (defined by anamnestic data on the first 
occurrence of the symptoms) were 33.6 +/- 11.5 years, 12.0+/- 2.8 years and 6.7+/-7.8 
years, respectively, with no differences between patients who received olanzapine and 
risperidone.  
All participants gave informed written consent for participation in the study, prior to 
blood sampling and after the remission of the illness were achieved. The study 
protocol was approved by the Hospital Ethical Committee of the Hospital Centre 
Zagreb and Hospital Ethical Committee of the psychiatric hospital “Sveti Ivan”. 
 
2.2. Procedure 
 
All subjects were weighted, their height was measured and body mass index (BMI) 
was calculated for each patient prior to olanzapine/risperidone administration. Body 
weight increase was assessed four months afterwards on outpatient visits. Olanzapine 
and risperidone were administered in open treatment, in fixed doses (olanzapine 10 
mg/day (n=56), or 20 mg/day (n=5) and risperidone 4mg/day (n=47). To assess and 
evaluate improvement of clinical psychotic symptoms and therapeutic response to an 
antipsychotic, all patients were rated using the Positive and Negative Syndrome Scale 
(PANSS) at two time points (initial and four months afterwards), by two experienced 
psychiatrists (VM and IS). Interrater reliability score was high, above 0.87. Clinical 
improvement was measured with total PANSS and positive, negative and general 
PANSS subscales percentages of change. Weight gain related to 
olanzapine/risperidone was defined as increase in bodyweight more than 7% of 
baseline body weight, according to The Federal Drug and Food Administration 
definition. 
 
2.3. Genotyping  
 
Genomic DNA was freshly isolated from leukocytes (EDTA-anticoagulated blood) by 
the salting out method (Miller el al., 1988). For analysis of -759C/T allelic variants of 
5-HT2C gene PCR-RFLP method was applied according to previously described 
procedure (Yuan et al., 2000; Pooley et al., 2004) with some modifications. By PCR 
method a fragment from –885 to -634 of the gene sequence was amplified using the 
following specific primers: forward 5’-ATC TCC ACC ATG GGT CTC GC-3’ and 
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reverse 5’-CAA TCT AGC CGC TCC AAA GG-3’. PCR was performed in 20µl 
reaction volume containing 1x PCR reaction buffer, 200ng of genomic DNA, 
200µmol/L of each dNTP, 0.3 µmol/L of each primer, 1.5 mmol/L MgCl2, and 2U of 
Taq DNA polymerase. The conditions for amplification were as follows: initial 
denaturing step of 94°C for 5 min, followed by 35 cycles of 95°C for 30 sec, 57°C for 
45 sec, 72°C for 1 min, and a final elongation step of 72°C for 10 min. 252 bp PCR 
product was then digested with Aci I restriction endonuclease into fragments 
depending on genotype (C→T substitution at –759 abolishes Aci I restriction site). 
With regard to the –759 polymorphisms, the C allele is denoted by 126 bp fragment 
and the T allele by a 160 bp fragment. 
Analysis of 2677 G/T/A polymorphisms in exon 21 of MDR1 and 3435C/T 
polymorphism in exon 26 were previously described in Bozina et al., (2006). 
 
2.4. Data analysis 
 
Binary logistic regression was used to predict weight gain from sociodemographic 
data (age, years of education), duration of illness, baseline body weight, baseline BMI 
(BBMI), baseline PANSS and all PANSS subscales, and dose of antipsychotics 
needed to achieve the remission of the symptoms. Differences among subjects with 
various genotype groups were determined by using analysis of variance. Fischer exact 
test was used for pair-wise comparisons of the allele (2X2) and genotype (2X3) 
frequencies between ≥7% and <7% groups. P value < 0.05 was considered statistically 
significant. Odds ratios (ORs) and confidence intervals (CIs) were calculated when 
appropriate. All statistical analyses were carried out using SPSS 11.5 (SSPS inc., 
Chicago, IL, USA) statistical software package. The sequential Bonferroni 
adjustments (Rice, 1989), using two different methods appropriate for dependent 
(genotype distribution depending on allelic frequency, and frequency of particular 
haplotype depending on the overall haplotype distribution) (Holm, 1979) and 
independent variables (loci and haplotypes) (Simes, 1986; Hochberg, 1988) were 
applied to correct for the effect of multiple tests.  
Afterwards, a test for Hardy-Weinberg equilibrium using Markov chain method (Guo 
and Thompson, 1992), as well as linkage-disequilibrium (LD) likelihood-ratio test 
between loci (Slatkin and Excoffier, 1996) were performed, as implemented in 
Arlequin ver. 3.01 (Excoffier et al., 2006). MDR1 haplotype frequencies were 
estimated using Expectation-Maximization algorithm implemented in the same 
program, leading to maximum likelihood estimates of haplotype frequency. Log 
likelihood ratio tests were performed to compare distributions of the estimated 
haplotypes between ≥7% and <7% groups.  
 
3. Results 
 
3.1. Allele and genotype frequencies of 5HT2C and MDR1 genes 
 
Frequencies of CC, CT and TT genotypes of -759C/T were 60, 42 and 6 respectively, 
of GG, GT, TT genotypes of exon 21 G2677T/A were 42, 53 and 13, respectively, 
whereas of CC, CT and TT genotypes of exon 26 C3435T MDR1 polymorphic locus 
were 24, 55 and 29, respectively. No significant deviations from the expected Hardy–
Weinberg proportions were observed in the sample (exon 21 G2677T, p=0.68; exon 
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26 C3435T, p=1) and also in ≥7% (exon 21 G2677T, p=0.38; exon 26 C3435T, p=1), 
or in <7% groups (exon 21 G2677T, p=1; exon 26 C3435T, p=0.79). Test results for 
linkage disequilibrium between loci exon 21 G2677T and exon 26 C3435T were 
found to be significant in the total sample (r2=0.3261, p<0.0001, χ2=32.56, d.f.=1), but 
also ≥7% (r2=0.2595, p=0.011, χ2=6.49, d.f.=1) and <7% groups (r2=0.3764, 
p<0.0001, χ2=25.80, d.f.=1) in the total sample. Only in ≥7% group among patients 
treated with olanzapine, when analyzed separately, LD between loci was not 
significant (p=0.134, χ2=2.23, d.f.=1). 
 
3.2. Allele, genotype and haplotype associations with weight gain 
 
After 4-months of treatment with SDAs, patients gained 3.5+/-4.2 kg or 5.5+/-6% 
(mean +/-SD) of their baseline body weight with no differences between patients 
treated with risperidone and olanzapine (data not shown).  
No differences in allele and genotype distributions of all studied genes were found 
when weight gain was divided as dichotomous trait in group of patients who gained 
more than 7% of their initial body weight and group of patients who gained less than 
7% of their initial body weight (Table 1). No statistical differences were found in 
distributions of the estimated MDR1 haplotypes between ≥7% and <7% groups, 
either. However, comparison of carriers of G2677/C3435 haplotype vs. others showed 
this haplotype to be less represented in the ≥7% group (χ2= 5.009, d.f.=1, p=0.025; 
OR=0.54, 95% CI 0.31-0.93). After correction for multiple testing this association 
would be close to statistical significance, but no reaching it (α=0.0125) (Table 2). 
 
3.3. Allele, genotype and haplotype associations with weight gain in risperidone 
treated patients 
 
Pair-wise comparisons of the allele and genotype frequency between ≥7% and <7% 
groups in the group of patients treated with risperidone revealed statistical difference 
in the distribution of 26 C3435T  variants (allele comparison with Fischer exact test 
2X2, p=0.015; OR=0.35, 95% CI 0.15-0.80 and genotype comparison with Fischer 
exact test 2x3 p=0.022) and statistical difference in the distribution of exon 21 
G2677T (Fischer exact test 2X2, p=0.031; OR=0.36, 95% CI 0.15-0.87). After 
correction for multiple testing, all mentioned association remained significant, with 
the exception of difference in the distribution of exon 21 G2677T (Table 1). 
Statistical differences were found in distributions of the estimated MDR1 haplotypes 
between ≥7% and <7% groups among risperidone treated patients (Log likelihood 
ratio test, χ2 = 7.928, d.f. =3, p=0.048). Subsequent analyses showed G2677/C3435 
haplotype to be less represented (Log likelihood ratio test, H1 vs. others χ2 = 7.509, 
d.f. =1, p= 0.006; OR=0.31, 95% CI 0.13-0.73) and 2677T/3435T haplotype to be 
overrepresented in the ≥7% group (Log likelihood ratio test, H4 vs. others χ2 = 4.539, 
d.f. =1, p= 0.033; OR=2.59, 95% CI 1.06-6.30). After correction for multiple testing 
in haplotype based analysis among the risperidone treated patients, all mentioned 
association remained significant, with the exception of difference in the distribution of 
2677T/3435T haplotype between ≥7% and <7%  (Table 2). 
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3.4. Allele and genotype associations with treatment response 
Although we observed similar trends in treatment response measured with changed 
PANSS score comparing G2766T and C3435T genotypes (GG<GT<TT and 
CC<CT<TT), differences reached statistical significance only when comparing 
changed positive PANSS sub scores between G2766T (mean +/- SD of GG:GT:TT 
were 53+/-16:53+/-15:64+/-9, p=0.047) and C3435T genotype (mean +/- SD of 
CC:CT:TT were 48+/-17:57+/-16:59+/-16, p=0.016). Binary logistic regression 
analysis established no confounding effects of age, duration of illness, dose of 
antipsychotics, baseline weight, BBMI, baseline PANSS and baseline values of all 
PANSS subscales on weight gain. There were no differences between groups of 
patients treated with olanzapine and risperidone in aforementioned variables. There 
were no statistically significant differences between genotype groups for each SNP in 
terms of age, duration of illness, dose of antipsychotics, baseline weight, BBMI and 
baseline PANSS. 
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4. Discussion 
 
Based on the main findings of this study, two conclusions might be drawn: (1) 759C/T 
polymorphism of the 5HT2C receptor might not play a significant role in susceptibility 
to weight gain in female schizophrenic patients; (2) MDR1 exon 21 G2677T and exon 
26 C3435T polymorphisms might have significant influence on SDAs-induced weight 
gain in female schizophrenic patients. 
We found no associations between SDAs-induced weight increase and -759C/T 
genotype in female schizophrenic patients. So far, results of association studies of 
759C/T variants and SDAs-induced weight gain produced conflicting results. Recent 
studies found less weight gain in subjects bearing T allele (Ellingrod et all., 2005; 
Miller et al., 2005; Templeman et al., 2005, Godlewska et al., 2006), while other 
reported opposite results (Basile et al., 2002, in male subjects), or found no 
associations (Basile et al., 2002, Tsai et al., 2002; Theisen et al., 2004; Godlewska et 
al., 2006 in females). A variety of possible factors could provide explanations for 
these differences. 
Compared to other studies, the majority of our patients had received no prior 
antipsychotic treatment, which limits the influence of one of the most confounding 
factors on the results. We included in the study only female subjects.  Previous studies 
reporting associations between T allelic variant and lower weight gain included male 
(Reynolds et al., 2002) or predominantly male subjects (Ellingrod et al., 2005; Miller 
et al., 2005; Templeman et al., 2005). In the recent study by Godlewska et al., (2006), 
authors found significant associations between T allelic variant and lower weight gain 
only in male subjects, whereas no association was found in female subjects. Since 
5HT2C is situated on X chromosome, sex of subjects might influence study results, i.e. 
the associations with 5HT2C might be more evident among male subjects. It is 
possible that SDAs induced weight gain in female schizophrenic patients may result 
from contributions from both allele variants. Study duration might greatly contribute 
to divergence among mentioned results. Templeman et al., (2005) found T variant to 
be overrepresented in <7% group at week 6 and after 9 months, but not at after 3-
month SDAs treatment suggesting that additional mechanisms of weight increase, 
including gene-environment interactions (Caspi et al., 2002) might be implicated 
during long term SDAs-treatment in schizophrenia. Those effects might be especially 
important for female population (Caspi et al., 2002). Our results are consistent with 
previous reports which are compatible in terms of sample size and sex (Basile et al., 
2002; Tsai et al., 2002; Theisen et al., 2004; Godlewska et al., 2006). Allele and 
genotype frequencies of 759C/T polymorphism in the studied population did not 
differ from reported results in other studies among Caucasian populations (i.e. Basile 
et al., 2002; Godlewska et al., 2006). 
Studies reporting the influence of polymorphic loci in exon 26 C3435T on MDR1 
expression so far produced conflicting results, as 3435T variant was found to be 
associated with lower MDR1 expression in the duodenum, and increased plasma 
levels of digoxin (Hoffmeyer et al., 2000), but also with lower plasma concentration 
of the digoxin in 3435T carriers according to other authors (Sakaeda et al., 2001). The 
same concerns studies which reported the influence of the exon 21 G2677T 
polymorphism on MDR1 expression and its effects on drug blood levels (Kim et al., 
2001; Tanabe et al., 2001).  
According to our findings, both studied MDR1 polymorphic loci, G2677T and 
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C3435T might contribute to weight gain, possibly producing a combined effect. 
Although we found less representation of G2677/C3435 haplotype in the ≥7% group, 
it did not reach statistical significance after correction for multiple testing. It is 
possible that observed associations account for the strong statistical significance 
which was revealed in the group of patients treated with risperidone. We found 
borderline overrepresentation of 2677T allele and overrepresentation 3435T allele in 
≥7% group among patients treated with risperidone. The strongest statically 
significant differences were observed in haplotype-based analyses, which showed 
G2677/C3435 haplotype to be significantly less represented and 2677T/3435T 
haplotype to be non significantly overrepresented in the ≥7% group. Our results might 
indicate lower P-gp expression of 3435T and 2677T allele compared to C3435T and 
G2677 allele, compatible with the studies by Tanabe et al., (2001) and Hoffmeyer et 
al., (2000). According to our results, we could assume that both, 3435T and 2677T (in 
lesser extent) variants were associated with lower P-gp function and higher 
risperidone accessibility to the brain. Higher risperidone concentrations in the brain of 
3435T and 2677T carriers compared to C3435 and G2677 carriers would allow 
stronger effects of risperidone, including its effects on risperidone-induced weight 
gain. Carriers of 2677T/3435T haplotypes would be prone to effects of risperidone 
treatment, including effects on weight gain, having higher risperidone brain 
concentrations, whereas carriers of G2677/C3435 haplotype would be more 
“resistant” to risperidone effects, including induced weight gain. This hypothesis is 
also supported by the finding of significantly better treatment response among carriers 
of 2677TT and 3435TT genotype, which was observed in this study, and compatible 
with previous studies (Bozina et al., 2006, Lin et al., 2006). That would suggest a 
pharmacokinetic effect of MDR1 on weight gain. Although no effects of 
antipsychotics' dose on weigh gain were found in this study, it might be because the 
majority of the patients were receiving the same dose in either risperidone and 
olanzapine treated groups. In contrast, 5HT2C genotype had no influence on treatment 
response. It might be possible several mechanisms (one of which is pharmacokinetic) 
are involved in SDAs induced weight increase.  
Compared to risperidone, which is considered a strong MDR1 substrate (Mahar Doan 
et al., 2002); olanzapine is an intermediate MDR1 substrate (Boulton et al., 2002). 
This fact could provide an explanation for the lack of associations between studied 
MDR1 variants and olanzapine-induced weight gain in our study and also in the study 
conducted by Lin et al., (2006), where negative association of olanzapine-induced 
weight gain and exon 26 C3435T and exon 21 G2677T MDR1 polymorphisms were 
reported.  
Although G2677T and C3435T genotype seem to influence MDR1 expression, other 
explanations are possible. Considering that exon 26 C3435T is a silent mutation 
(Hoffmeyer et. al., 2000), it might be possible that observed associations are due to its 
linkage disequilibrium with exon 21 G2677T, or it might be possible that both 
polymorphic loci are in linkage disequilibrium with another MDR1 mutation, for 
example exon 12 (Hoffmeyer et. al., 2000). Therefore, although we determined 
suggestive factors for susceptibility to risperidone induced weight gain in 
schizophrenia in females, these results require replication, also including analysis of 
other MDR1 polymorphic loci. Allele and genotype frequencies in the studied 
population did not differ from results reported in other European regions (Hoffmeyer 
et. al., 2000; Fromm, 2002). 
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There were several limitations in this study that should be acknowledged. First, as 
olanzapine and risperidone blood concentrations were not measured in this study, we 
are able to present only indirect associations between the MDR1 polymorphisms and 
risperidone-induced weight gain. Furthermore, we carefully observed the factors that 
could have influenced antipsychotic dose as smoking, metabolic disturbances and 
renal functions..). It could also be argued that plasma level of prescribed drug is useful 
for indirect assessment of compliance, as treatment compliance might be critical for 
psychiatric patients (Licinio and Wong, 2005). However, since none of the patients 
showed the worsening of symptoms after the initial improvement and after they were 
discharged and they came to outpatients visits regularly as proscribed by the 
psychiatrist, we assumed they were taking drugs as proscribed. Second, we point out 
the relatively small number of subjects, especially after their division in different 
SDAs groups. This effect could be especially important in the analysis of -759C/T 
polymorphic loci, especially considering that its effects might be less evident in 
female compared to male patients. Third, caloric input was not measured and patients 
were not controlled for this, which might have confounded the results. 
Finally, we included only female subjects in the study, who, although setting a 
limitation to generalizing the findings to male subjects with schizophrenia, 
contributed at the same time to the homogeneity of the study sample since gender 
differences in the course of illness and also in the SDAs-induced weight gain have 
been described (Babigian, 1985; DeLisi, 1992; Basson et al., 2001).  As a strong point 
of this study we emphasize that the majority of our patients were drug naive prior to 
the beginning of the study, and the rest stopped taking their medication prior to their 
enrolments in the study, limiting the influence of one of the most confounding factors 
in previous studies. 
 
Conclusion 
In sum, we found no associations between olanzapine and risperidone-induced weight 
increase and -759C/T genotype. However, we found less representation of the 
G2677/C3435 among schizophrenic female patients who gained significant weight 
probably accounting for the statistically significant less representation of that 
haplotype in risperidone treated patients. Furthermore, we found borderline 
overrepresentation of 2677T, significant overrepresentation of 3435T variant and 
borderline overrepresentation of 2677T/3435T haplotype among patients who gained 
significant weight following risperidone treatment. Therefore, carriers of MDR1 
2677T and 3435T variants, and especially 2677T/3435T haplotype might be prone to 
risperidone induced weight gain. However, because of the limitations of our sample, 
these results should be taken as suggestive and require replication studies with careful 
characterization of confounding factors like food intake and energy expenditure, 
especially with samples of different ethnic origin. 
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Table 1. Distribution of allele and genotype frequencies of 5HT2C receptor -759C/T and MDR1 exon 
21 G2677T and exon 26 C3435T polymorphisms in weight gain ≥ 7% and weight gain < 7% groups in 
female schizophrenic patients in total sample and risperidone-treated patients  
   Total sample (n=108) Risperidone-treated patients ( n=47) 
Locus   ≥ 7% 
n=49 
< 7% 
n=59 
 ≥ 7% 
n=23 
< 7% 
n=24 
Allele aC 67 95 cC 30 39 
 T 31 23 T 16 9 
Genotype bCC 22 38 dCC 9 15 
 CT 23 19 CT 12 9 
5HT2C 
-759C/T 
 TT 4 2 TT 2 0 
Allele aG 56 81 cG* 24 36 
 T 42 37 T 22 12 
Genotype bGG 14 28 d GG 6 13 
 GT 28 25 GT 12 10 
MDR 1 
exon 21 
G2677T 
 TT 7 6 TT 5 1 
Allele aC 40 63 cC* 16 29 
 T 58 55 T 30 19 
Genotype bCC 8 16 cCC* 2 7 
 CT 24 31 CT 12 15 
MDR 1 
exon 26 
C3435T 
 TT 17 12 TT 9 2 
 
aFischer exact 2X2: 5HT2C -759C/T p=0.057; exon 21 G2677T, p=0.089; exon 26 C3435, p=0.076 
bFischer exact 2X3: 5HT2C -759C/T p=0.103; exon 21 G2677T, p=0.133; exon 26 C3435, p=0.186 
cFischer exact 2X2: 5HT2C -759C/T p=0.103; exon 21 G2677T, p=0.031*; exon 26 C3435, p=0.015* 
dFischer exact 2X3: 5HT2C -759C/T p=0.129; exon 21 G2677T, p=0.072; exon 26 C3435, p=0.022* 
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Table 2. Haplotype frequencies (proportions) of the two SNP loci: exon 21 G2677T and exon 26 
C3435T in weight gain ≥ 7% and weight gain < 7% groups in female schizophrenic patients in total 
sample and risperidone-treated patients. Haplotype frequency was determined using the statistical 
program based on the EM algorithm. 
 
 
 
 
 
Log likelihood ratio test, aχ2 = 5.435, d.f. =3, p=0.143, H1 vs. others χ2= 5.009, d.f.=1, p= 0.025 
Log likelihood ratio test,  bχ2 = 7.928, d.f. =3, p=0.048; H1 vs. others χ2 = 7.509, d.f.=1, p= 0.006; H4 
vs. others χ2 = 4.539, d.f.=1, p= 0.033 
 
 
 
    
a Total sample 
n=108 
b
 Risperidone-treated patients n=47 
Haplotype G2677T 
MDR1 
C3435T 
MDR1 
weight gain ≥ 7%   
n=49 
weight gain < 7%  
n=59 
weight gain ≥ 7%   
n=23 
weight gain < 7%  
n=24 
H1 G C 35 (33) 60 (50) 14 (28) 28 (58) 
H2 G T 21 (24) 21 (19) 10 (24) 8 (17) 
H3 T C 5 (8) 3 (3) 2 (6)  1 (3) 
H4 T T 37 (35) 34 (28) 20 (42) 11 (22) 
